Sara A. Hurvitz

30.6k total citations · 6 hit papers
375 papers, 11.0k citations indexed

About

Sara A. Hurvitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sara A. Hurvitz has authored 375 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 303 papers in Oncology, 212 papers in Pulmonary and Respiratory Medicine and 69 papers in Cancer Research. Recurrent topics in Sara A. Hurvitz's work include Advanced Breast Cancer Therapies (188 papers), HER2/EGFR in Cancer Research (159 papers) and Cancer Treatment and Pharmacology (139 papers). Sara A. Hurvitz is often cited by papers focused on Advanced Breast Cancer Therapies (188 papers), HER2/EGFR in Cancer Research (159 papers) and Cancer Treatment and Pharmacology (139 papers). Sara A. Hurvitz collaborates with scholars based in United States, Spain and France. Sara A. Hurvitz's co-authors include Hope S. Rugo, Johannes Ettl, Aditya Bardia, Lida A. Mina, Dennis J. Slamon, Anthony Gonçalvès, Jennifer K. Litton, Young‐Hyuck Im, Parvin F. Peddi and Joanne L. Blum and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Sara A. Hurvitz

358 papers receiving 10.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

2019 591 citations Seock‐Ah Im, Aditya Bardia et al. New England Journal of Medicine profile →
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

2017 337 citations Sara A. Hurvitz, Miguel Martín et al. profile →
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

2024 71 citations Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology profile →
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

2024 53 citations Javier Cortés, Sara A. Hurvitz et al. profile →

Peers

Countries citing papers authored by Sara A. Hurvitz

Since Specialization

Citations

This map shows the geographic impact of Sara A. Hurvitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara A. Hurvitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara A. Hurvitz more than expected).

Fields of papers citing papers by Sara A. Hurvitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara A. Hurvitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara A. Hurvitz. The network helps show where Sara A. Hurvitz may publish in the future.

Co-authorship network of co-authors of Sara A. Hurvitz

This figure shows the co-authorship network connecting the top 25 collaborators of Sara A. Hurvitz. A scholar is included among the top collaborators of Sara A. Hurvitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara A. Hurvitz. Sara A. Hurvitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination 2025 ·Cancer ·Julienne E. Bower, (unknown), Patricia A. Ganz, Michael R. Irwin, Steve W. Cole, Laura Petersen, Arash Asher, Sara A. Hurvitz, Catherine M. Crespi	0
2	Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial 2025 ·Clinical Cancer Research ·Peter A. Fasching, Dennis J. Slamon, Zbigniew Nowecki, (unknown), Daniil Stroyakovskiy, DA Yardley, Chiun‐Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín, Hope S. Rugo, Sherene Loi, Sara A. Hurvitz, Michael Untch, Karen Afenjar, Rodrigo Fresco, Andriy Danyliv, (unknown), (unknown), Gabriel N. Hortobágyi	2
3	Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort 2024 ·Cancer Research ·Erika Hamilton, Rinath Jeselsohn, Sara A. Hurvitz, Dejan Juric, Hyo S. Han, Melinda L. Telli, (unknown), Rita Nanda, Yuanyuan Zhang, Weiwei Tan, Elizabeth K. Duperret, Eric Zhi, (unknown), Anne F. Schott	2
4	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ·Journal of Clinical Oncology ·Erika Hamilton, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, (unknown), José Luiz Pedrini, Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, (unknown), Shahid Ashfaque, (unknown), Anton Egorov, Javier Cortés	5
5	390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial 2023 ·Annals of Oncology ·Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, (unknown), Pamela N. Münster, Bruno Fang, (unknown), (unknown), Richard Gedrich, Eric Zhi, (unknown), Weiwei Tan, (unknown), Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz	12
6	Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records 2023 ·JCO Oncology Practice ·Letizia Polito, (unknown), Sara A. Hurvitz, Chau T. Dang, Adam Knott, (unknown), Eleonora Restuccia, (unknown), Sandra M. Swain	0
7	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer 2021 ·Clinical Cancer Research ·Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, (unknown), Simon Waters, Sara A. Hurvitz, Beverly Moy, Sung‐Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald Wallweber, Judith D. Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge	15
8	A careful reassessment of anthracycline use in curable breast cancer 2021 ·npj Breast Cancer ·Sara A. Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark D. Pegram, John Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon	33
9	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response 2021 ·Nature Cancer ·Katherine McNamara, Jennifer L. Caswell‐Jin, Rohan P. Joshi, Zhicheng Ma, Eran Kotler, Gregory R. Bean, Michelle Kriner, Zoey Zhou, Margaret L. Hoang, Joseph Beechem, Jason J. Zoeller, Michael F. Press, Dennis J. Slamon, Sara A. Hurvitz, Christina Curtis	57
10	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs 2019 ·Clinical Cancer Research ·Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb	23
11	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) 2018 ·Clinical Cancer Research ·Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva‐Maria Grischke, Lida A. Mina, Judith Balmañà, Peter A. Fasching, Sara A. Hurvitz, Andrew Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson	88
12	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation breakdown → 2018 ·New England Journal of Medicine ·Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martín, Henri Roché, Young‐Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia Cristina Tudor, Alison L. Hannah, W. Eiermann, Joanne L. Blum	1401
13	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial 2018 ·Journal of Clinical Oncology ·Aditya Bardia, Marina Parton, Sherko Kümmel, Laura García‐Estévez, Chiun‐Sheng Huang, Javier Cortés, Manuel Ruíz‐Borrego, Melinda L. Telli, Paloma Martín-Martorell, Rafael López‐López, J. Thaddeus Beck, Roohi Ismail‐Khan, Shin‐Cheh Chen, Sara A. Hurvitz, Ingrid A. Mayer, D. Carreon, Scott B. Cameron, Serena G. Liao, José Baselga, Sung‐Bae Kim	55
14	Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation 2018 ·Cancer Research ·Jennifer K. Litton, HS Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung Ho Lee, Louis Fehrenbacher, Rinat Yerushalmi, (unknown), Miguel Martín, Henri Roché, Y-H Im, (unknown), (unknown), (unknown), W. Eiermann, JL Blum	40
15	Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer 2018 ·Clinical Cancer Research ·Silvia C. Formenti, Percy Lee, Sylvia Adams, Judith D. Goldberg, Xiaochun Li, (unknown), Josephine A. Ratikan, Carol Felix, Lin Hwang, Kym F. Faull, James Sayre, Sara A. Hurvitz, John A. Glaspy, Begoña Comı́n-Anduix, Sandra Demaria, Dörthe Schaue, William H. McBride	205
16	Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. 2016 ·PubMed ·Bingnan Zhang, Sara A. Hurvitz	14
17	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT 2014 ·Clinical Cancer Research ·Neil A. O’Brien, (unknown), Tong Luo, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon	93
18	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer 2013 ·Clinical Cancer Research ·Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, José Manuel Pérez-García, Sara A. Hurvitz, Nicholas C. Turner, Hope S. Rugo, John W. Smith, Stéphanie Deudon, Michael Shi, Yong Zhang, Andrea Kay, Diana Graus Porta, A. Yovine, José Baselga	251
19	Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab 2010 ·Journal of Clinical Oncology ·Fabrice André, Mario Campone, Ruth O’Regan, C. Manlius, Cristian Massacesi, (unknown), Pabak Mukhopadhyay, Jean‐Charles Soria, Michael Naughton, Sara A. Hurvitz	148
20	Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma 2009 ·Clinical Cancer Research ·Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig, Betsy LaPlant, Brian Kabat, (unknown), Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman	263

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact